🇺🇸 Genotropin (somatropin) in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Myocardial Infarction — 1 report (10%)
  2. Asthenia — 1 report (10%)
  3. Bronchopneumopathy — 1 report (10%)
  4. Condition Aggravated — 1 report (10%)
  5. Craniopharyngioma — 1 report (10%)
  6. Drug Administration Error — 1 report (10%)
  7. Fatigue — 1 report (10%)
  8. Flank Pain — 1 report (10%)
  9. Glomerulonephritis Proliferative — 1 report (10%)
  10. Growth Hormone Deficiency — 1 report (10%)

Source database →

Other Endocrinology approved in United States

Frequently asked questions

Is Genotropin (somatropin) approved in United States?

Genotropin (somatropin) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Genotropin (somatropin) in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.